BV421 Mouse Anti-Human Podoplanin  Clone  LpMab-17   (RUO)

Brand
BD Horizon™
Alternative Name
PDPN; T1-alpha (T1A); GP36; GP40; OTS8; T1A2; TI1A; T1A-2; AGGRUS; PA2.26
Concentration
0.2 mg/ml
Isotype
Mouse BALB/c IgG1, κ
Reactivity
Human (QC Testing) 
Application
Flow cytometry (Routinely Tested) 
Immunofluorescence, Immunohistochemistry-frozen (Tested During Development) 
Immunohistochemistry-paraffin (Reported) 
Immunogen
Human PDPN Transfected Cell Line
Storage Buffer
Aqueous buffered solution containing BSA and ≤0.09% sodium azide.
Regulatory Status
RUO

Regulatory Status Legend

RUO
For Research Use Only. Not for use in diagnostic or therapeutic procedures.
RUO (GMP)
For Research Use Only. Not for use in diagnostic or therapeutic procedures. Although not required, these products are manufactured in accordance with Good Manufacturing Practices.
GPR
General Purpose Reagent
IVD
For In Vitro Diagnostic Use.
ASR
Analyte Specific Reagent. Analytical and performance characteristics are not established.

Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.

Sizes
50 µg
Catalog No.
566456
List Price

$280.00

Your Price

Unit
EA (1 Each)
Quantity

  1. Astarita JL, Acton SE, Turley SJ. Podoplanin: emerging functions in development, the immune system, and cancer.. Front Immunol. 2012; 3:283. View reference

  2. Chang JE, Turley SJ. Stromal infrastructure of the lymph node and coordination of immunity. Trends Immunol.. 2015; 36(1):30-9. View reference

  3. Dang Q, Liu J, Li J, Sun Y. Podoplanin: a novel regulator of tumor invasion and metastasis. Med Oncol. 2014; 31(9):24. View reference

  4. Kato Y, Ogasawara S, Oki H, et al. Novel Monoclonal Antibody LpMab-17 Developed by CasMab Technology Distinguishes Human Podoplanin from Monkey Podoplanin. Monoclon Antib Immunodiagn Immunother. 2016; 35(2):109-16. View reference

  5. Pan Y, Xia L. Emerging roles of podoplanin in vascular development and homeostasis. Front Med. 2015; 9(4):421-30. View reference

  6. Retzbach EP, Sheehan SA, Nevel EM, et al. Podoplanin emerges as a functionally relevant oral cancer biomarker and therapeutic target. j.oraloncology. 2018; 78:126-136. View reference

  7. Ugorski M, Dziegiel P, Suchanski J. Podoplanin - a small glycoprotein with many faces. Am J Cancer Res. 2016; 6(2):370-86. View reference

566456 Rev. 2